Josh Ofman

President & CMO
GRAIL
Josh Ofman, MD, MSHS, is President and Chief Medical Officer at GRAIL. Josh also serves on the Board of Directors of Cell BT, Inc, an immuno-therapy company focused on the discovery and development of innovative cancer therapeutics. Previously, Josh spent more than 15 years at Amgen, where he most recently held the role of Senior Vice President, Global Value, Access and Policy. Prior to that, Josh was a faculty member in the Department of Medicine and Health Services Research at University of California, Los Angeles (UCLA) School of Medicine, Cedars-Sinai Medical Center, as well as Senior Vice President of Zynx Health Inc., a subsidiary of Cerner Corp. Josh holds a BA in history and philosophy of science from the University of California, Berkeley, and an MD from the University of California, Irvine, School of Medicine. Josh also has an MSHS from the UCLA School of Public Health.

Sessions by Josh Ofman

03:45 PM - 04:20 PM
Life & Health Track: Islander C 

How the Life Insurance Industry is Embracing Innovation to Detect Cancer Early

What do Munich Re, a major global reinsurer, John Hancock, a life insurance carrier, and GRAIL, the makers of Galleri‚ď°, a multi-cancer early detection test have in common?  Saving lives by detecting cancer early when it can be cured.

Join us to hear from Marc Giguere, President & CEO, Munich Re Life US, Brooks Tingle, the CEO of John Hancock and Josh Ofman, President of Grail as they discuss how together, they are changing the trajectory of cancer mortality one policyholder at a time.

Learn how you can be on the cutting edge of innovation and technology.

Contact Us

Thank you for your interest in InsureTech Connect! We look forward to hearing from you. Contact us below with general inquiries.